Technical Momentum and Indicator Overview
The recent technical parameter adjustment for Lupin Ltd. reflects a strengthening price momentum. The stock closed at ₹2,409.90 on 28 Jul 2026, marking a 1.71% gain from the previous close of ₹2,369.45. Intraday, it traded between ₹2,371.00 and ₹2,431.85, inching closer to its 52-week high of ₹2,530.00, while comfortably above the 52-week low of ₹1,838.65.
On the weekly and monthly charts, the Moving Average Convergence Divergence (MACD) indicator remains bullish, reinforcing the positive momentum. The weekly MACD confirms upward momentum, while the monthly MACD sustains this bullish stance, suggesting medium to long-term strength. However, the Relative Strength Index (RSI) presents a mixed picture: weekly RSI shows no clear signal, whereas the monthly RSI is bearish, indicating some caution over potential overbought conditions or short-term corrections.
Bollinger Bands on the weekly timeframe are bullish, signalling price expansion and volatility in favour of upward movement. The monthly Bollinger Bands are mildly bullish, suggesting a steady but less aggressive trend. Daily moving averages are firmly bullish, supporting the recent price gains and indicating that short-term momentum is robust.
Additional Technical Signals and Trend Analysis
The Know Sure Thing (KST) indicator, which helps identify major price cycles, is bullish on the weekly scale but mildly bearish monthly, echoing the RSI’s cautionary tone for longer-term investors. Dow Theory analysis shows no clear trend on the weekly chart but confirms a bullish trend on the monthly timeframe, reinforcing the medium-term positive outlook.
On-Balance Volume (OBV), a volume-based indicator, shows no trend weekly and a mildly bearish stance monthly, suggesting that volume support for the price rally is not yet fully convincing over the longer term. This divergence between price momentum and volume could warrant close monitoring for potential shifts in investor participation.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Performance Context: Lupin vs. Sensex
Examining Lupin’s returns relative to the benchmark Sensex index highlights the stock’s outperformance over multiple time horizons. Over the past week, Lupin declined by 2.76%, slightly underperforming the Sensex’s 1.12% fall. However, over the last month, Lupin gained 2.89% while the Sensex dipped 0.34%, signalling a recovery phase for the stock.
Year-to-date, Lupin has surged 14.11%, significantly outperforming the Sensex’s negative 9.84% return. Over the last year, Lupin’s return of 23.60% starkly contrasts with the Sensex’s 5.68% decline, underscoring the stock’s resilience amid broader market weakness.
Longer-term performance is even more impressive. Over three years, Lupin’s cumulative return stands at 145.90%, vastly exceeding the Sensex’s 15.95%. Over five years, Lupin’s 116.86% gain dwarfs the Sensex’s 46.13%. However, over a decade, Lupin’s 40.20% return trails the Sensex’s 174.18%, reflecting the benchmark’s broader market leadership over the very long term.
Mojo Score Upgrade and Market Positioning
Reflecting these positive technical developments and strong relative performance, Lupin’s Mojo Score has been upgraded to 84.0, earning a “Strong Buy” grade as of 21 Jul 2026, up from a previous “Buy” rating. This upgrade by MarketsMOJO highlights the stock’s enhanced attractiveness based on a comprehensive assessment of fundamentals, valuations, and technicals.
As a mid-cap stock within the Pharmaceuticals & Biotechnology sector, Lupin’s improved technical trend from mildly bullish to bullish aligns with its sectoral growth prospects and ongoing investor interest in healthcare innovation and pharmaceutical manufacturing.
Technical Outlook and Investor Implications
The bullish signals from MACD and moving averages, combined with the positive weekly Bollinger Bands and KST indicators, suggest that Lupin is poised for further upward momentum in the near term. The daily moving averages’ bullish stance supports this view, indicating that short-term traders may find favourable entry points.
However, the bearish monthly RSI and mildly bearish monthly KST and OBV indicators counsel some caution for longer-term investors, signalling potential overextension or a need for consolidation before the next leg higher. Investors should monitor volume trends closely to confirm sustained buying interest.
Given Lupin’s strong relative performance versus the Sensex and its upgraded Mojo Grade, the stock appears well-positioned to capitalise on sector tailwinds and technical momentum. Nonetheless, prudent risk management and attention to monthly indicator signals remain advisable.
Lupin Ltd. caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Conclusion: A Bullish Technical Reset with Cautious Optimism
Lupin Ltd.’s recent technical parameter change from mildly bullish to bullish marks a significant shift in market sentiment. The convergence of bullish MACD readings, supportive moving averages, and positive weekly Bollinger Bands underpin a constructive price momentum outlook. This is further validated by Lupin’s strong relative returns against the Sensex over multiple periods and its upgraded Mojo Grade to “Strong Buy.”
Nonetheless, mixed signals from monthly RSI, KST, and OBV indicators suggest that investors should remain vigilant for potential short-term volatility or consolidation phases. The stock’s mid-cap status and sector fundamentals provide a solid foundation for growth, but volume confirmation and trend sustainability will be key to maintaining the bullish trajectory.
Overall, Lupin Ltd. presents a compelling technical and fundamental case for investors seeking exposure to the Pharmaceuticals & Biotechnology sector, combining robust momentum with attractive valuation and quality metrics.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
